HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Zurich
About this trial
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participate din the study in 2017 to undergo follow-up examinations in 2024, in order to allow comparisons of current results with baseline data from 2017.
Eligibility criteria
Qualifiers
Permanently living >2500 m
Written informed consent
Disqualifiers
Highlanders who cannot follow the study investigations,
Patients with moderate to severe concomitant lung disease (FEV1<70% or forced vital capacity <70%), severe parenchymal lung disease, heavy smoking >20 cigarettes/day or >20 pack-years.
Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
120 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
University of Zurich
Lead sponsor
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Collaborator
Source ClinicalTrials.gov